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a b s t r a c t
Although lithium has been the ﬁrst line agent in the treatment of bipolar disorder (BD), few studies have
evaluated lithium’s efﬁcacy in mania with psychosis and its association with later response. Furthermore,
given the widespread concern about antipsychotic side effects, answering a question about whether
lithium alone can manage to treat both psychotic and non-psychotic mania seems a very relevant one.
The present study addresses the antipsychotic efﬁcacy of lithium monotherapy in acute mania and early
improvement of psychotic symptoms as a predictor of later response of manic symptoms. Forty-six
patients presenting a manic episode (32 with psychotic features and 14 subjects without psychotic
features) were treated for 4 weeks with lithium monotherapy and evaluated weekly using the Young
Mania Rating Scale (YMRS). Subjects with rapid cycling, substance abuse/dependence, or mixed episodes
were excluded. The overall antimanic efﬁcacy of lithium in psychosis vs. non-psychosis groups was
evaluated. In addition, early improvement of psychotic symptoms and its prediction of subsequent
response (>50% decrease in total YMRS scores) or remission were evaluated. Lithium showed a similar
efﬁcacy in both psychosis and non-psychosis mania. Early improvement of psychotic symptoms was
associated with clinical response and remission at endpoint.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Psychotic symptoms are present in about half of the manic
episodes in bipolar disorder (BD) (Pope and Lipinski, 1978; Coryell
et al., 2001; Keck et al., 2003). Psychosis in BD has been associated
with poorer cognitive functioning (Bora et al., 2010), longer periods
of active illness (Coryell et al., 2001), and higher relapse rates
(Tohen et al., 1990). Although lithium is considered a ﬁrst line agent
for treating acute mania (Yatham et al., 2009), only a few studies
have systematically evaluated lithium’s efﬁcacy for the treatment of
mania with psychosis (Prien et al., 1972; Small et al., 1995; Swann
et al., 2004) and none have addressed the time course of action
onset. This seems to be mostly due to the widespread practice of
combining antipsychotics with mood stabilizer agents within the
ﬁrst weeks of treatment (McElroy et al., 1996), which has been
recommended for both psychosis and non-psychosis mania
(Goodwin, 2009; Malhi et al., 2009; Yatham et al., 2009).
Few studies have evaluated early improvement in bipolar mania
as a predictor of outcome (Houston et al., 2010; Kemp et al., 2011a;
Ketter et al., 2010). It has been shown that improvement of
psychotic (Ketter et al., 2010) and manic symptoms (Houston et al.,
2010; Kemp et al., 2011a) in the ﬁrst week predicts later response
with second-generation antipsychotics. However, only a few
predictors of response with lithium are available (Grandjean and
Aubry, 2009) and no study has evaluated early improvement of
psychotic symptoms with lithium and its potential role as
a predictor of later response.
The present study aims to evaluate: 1) lithium’s efﬁcacy in
mania with psychosis. Results were subsequently compared with
a comparison group of concurrently-recruited, mania without
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psychosis treated with lithium; 2) whether or not lithium induces
early improvement of psychotic symptoms, and 3) whether early
improvement of psychotic features of mania is associated with later
response and remission.
2. Materials and methods
This study is a post-hoc analysis from a larger 4-week,
randomized, double-blind, trial in bipolar mania comparing the
efﬁcacy of lithium plus placebo vs. lithium plus other drugs
(Machado-Vieira et al., 2008). The present analysis is performed in
the lithium plus placebo arm of the original trial. Forty-six inpa-
tients, aged 18e65 years, with a diagnosis of manic episode with
psychosis (n ¼ 32) or without psychotic features (n ¼ 14;
comparison group) by means of the Structured Clinical Interview
for Axis I DSM-IV-TR Disorders, Research Version, Patient Version
(First et al., 2001) were evaluated. All patients were enrolled
between September 2003 and September 2006 at the Bipolar
Disorder Research Center, Espirita Hospital of Porto Alegre, Brazil.
Subjects were required to present a score of greater than or equal to
22 on YMRS (Young et al., 1978) at baseline. All subjects were in
good physical health (determined by medical history, physical
examination and blood tests) and free of comorbid substance abuse
or dependence for at least 5 weeks prior to screen. Patients had not
taken any psychopharmacologic treatment for at least 4 weeks
before admission. Other exclusion criteria included rapid cycling,
mixed episode, previous history of refractoriness to lithium, or
other current axis I psychiatric disorder.
On the ﬁrst day, patients were started on lithium carbonate
600 mg/day, and subsequent dosage adjustments were allowed at
a ﬂexible fashion, aiming to achieve therapeutic levels in the
plasma (0.6e1.2 mmol/L), and then adjusted according to clinical
improvement. Diazepam up to 20 mg/day was allowed as supple-
mentary medication for agitation during the 4-week study period,
except for the day prior to clinical assessment with the YMRS;
physical restraint was used when necessary. In accordance with the
Declaration of Helsinki, the local institutional review board
approved the study and all subjects and/or family members
provided written informed consent before entry into the study.
2.1. Outcome measures
Subjects were assessed with the YMRS on a weekly basis from
baseline to week 4. Statistical analyses were made for baseline, 1-
week, and 4-week (endpoint) measures, using the last observa-
tion carried forward (LOCF) or linear mixed model when data were
missing. Psychosis in mania was deﬁned as the presence of delu-
sions and hallucinations, i.e., YMRS item-8 (Content) score ¼ 8
(maximum score). Early improvement in psychotic symptoms
(early improvers) was deﬁned as improvement of delusions and
hallucinations after 1 week of treatment, based on a decrease25%
in the YMRS item-8 (Content) score. Clinical response was deﬁned
as a decrease of 50% or more in the YMRS at the endpoint (week 4).
Remitters were those who had YMRS 12 at endpoint. An addi-
tional analysis using a more stringent criterion at endpoint (YMRS
score 7) was also performed.
2.2. Statistical analysis
Demographic and clinical characteristics of psychosis and non-
psychosis mania at baseline were compared with the Chi-square
test for categorical data. A linear mixed model was used to
examine the time course of improvement with lithium treatment in
mania with and without psychosis and to compare diazepam use
between groups. Also, Student’s t test (normal) or ManneWhitney
(non-normal distribution) tests were used for continuous variables.
Wilcoxon signed ranks test was used to compare YMRS scores at
baseline and endpoint. Spearman test was used to correlate
decrease in the YMRS item-8 and total scores. Statistical signiﬁ-
cance was set at p < 0.05 (two-tailed). All statistical analyses were
conducted in the SPSS 16.0 software. In the psychosis mania group,
additional analyses were conducted in order to determine the
prognostic value of early improvement in psychotic symptoms at
week 1 in predicting endpoint (week 4) response or remission.
Sensitivity, speciﬁcity, and positive and negative predictive values
(see Kemp et al., 2011a for further details) were calculated.
3. Results
3.1. Clinical and demographical data
Demographic and clinical data for the psychosis and non-
psychosis mania groups are summarized in Table 1. There were
no differences between groups except for a larger number of
women in the mania without psychosis group.
3.2. Mania with and without psychosis has similar severity and also
similar improvement with lithium treatment
YMRS total scores did not show signiﬁcant differences between
mania with and without psychosis (F ¼ 0.27, df ¼ 1, 42, p ¼ 0.87),
nor signiﬁcant interaction between group and time (F¼ 1.16, df¼ 3,
110, p ¼ 0.33) (Fig. 1). When baseline was included as a time point
in the mixed model, also no signiﬁcant difference between YMRS
total scores of mania with and without psychosis was found
(F¼ 1.76, df¼ 1, 46, p¼ 0.19) and no signiﬁcant interaction between
group and time (F ¼ 0.88, df ¼ 4, 151, p ¼ 0.48). There were no
Table 1
Demographic variables and clinical characteristics of psychosis and non-psychosis
groups compared.
YMRS item Psychosis
(n ¼ 32)
Non-psychosis
(n ¼ 14)
p
Gender
Male/female, n (%) 16(50)/16(50) 1(7)/13(93) 0.006*,a
Age
Age, year (SD) 28.8 (8.5) 30.7 (8.7) 0.36
Race
White, n (%) 27 (84) 11 (79) 0.63a
Black, n (%) 5 (15) 3 (21)
Age at onset, year (SD) 22.7 (3.9) 20.9 (3.8) 0.16b
Duration of illness, year (SD) 8 (7.7) 7.9 (6.9) 0.97b
Number of mood episodes,
year (SD)
4.5 (3.5) 5.6 (3.2) 0.35b
Number of manic episodes
(SD)
2.7 (2.2) 4.1 (3) 0.06c
Type of ﬁrst episode
Mania, n (%) 16 (50) 9 (64) 0.65a
Depression, n (%) 12 (37) 4 (29)
Mixed, n (%) 4 (13) 1 (7)
Number of past hospitalizations
(SD)
2.8 (2.7) 3.5 (3) 0.52c
Suicidal attempts (SD) 1.6 (2.1) 0.7 (1.6) 0.17c
Familiar history of bipolar
disorder
16 (50) 8 (57) 0.65a
Present, n (%)
Serum lithium at endpoint,
mEq/L (SD)
0.96 (0.2) 0.93 (0.19) 0.91c
Diazepam use, mg (SD) 184.7 (122) 134.3 (127) 0.81d
YMRSe YoungMania Rating Scale. SD e standard deviation. *Signiﬁcantly different.
a Chi-square.
b Student’s T test.
c ManneWhitney test.
d Linear mixed model.
R.T. de Sousa et al. / Journal of Psychiatric Research 46 (2012) 1564e1568 1565
signiﬁcant differences between psychosis and non-psychosis
groups in YMRS single items, except for greater YMRS-item 11
scores in the psychosis group (data not shown).
Since there was a signiﬁcant gender difference between
psychosis and non-psychosis groups, additional linearmixedmodel
analyses were performed in female patients and showed no
signiﬁcant differences in YMRS total scores between psychosis and
non-psychosis groups, respectively (F¼ 0.21, df¼ 1, 27, p¼ 0.65 and
F ¼ 1.2, df ¼ 1, 30, p ¼ 0.28) and no signiﬁcant interaction between
group and time (F¼ 0.86, p¼ 0.46; F¼ 0.73 p¼ 0.57). Diazepam use
and side effects were not signiﬁcantly different between psychosis
and non-psychosis groups (data not shown).
Lithium treatment was associated with a signiﬁcant improve-
ment of manic symptoms in the psychosis group from baseline to
endpoint (YMRS: 35.1 8.6 vs. 14.8  12.5, respectively, p < 0.001).
At endpoint, in the psychosis mania group (n ¼ 32), 63% achieved
clinical response, and 50% remitted (YMRS  12). Also, 34%
remitted using more stringent criteria (YMRS  7). In the non-
psychosis group (n ¼ 14), lithium also showed a signiﬁcant
improvement of manic symptoms from baseline to endpoint
(YMRS: 31  8.6 vs. 12.6  12.7, respectively, p ¼ 0.002). Sixty four
percent showed both response and remission (YMRS  12) at the
endpoint, while half of patients presented remission accordingly to
the more stringent criteria.
Changes from baseline to endpoint of psychotic symptoms in
YMRS item-8 (Content) correlatedwith improvement of YMRS total
scores (p < 0.001) in psychotic mania (Fig. 2).
3.3. Early improvement in psychotic symptoms predicts later
response and remission
Sixteen (50%) subjects in psychosis mania group presented an
early improvement of delusions and hallucinations after one week
of lithium treatment. Among early improvers, 15 achieved clinical
response (PPV ¼ 94%), 12 remitted (PPV ¼ 75%, YMRS  12), and 8
presented remission (PPV¼ 50%) at endpoint with a more stringent
criteria (YMRS  7) (Table 2). Among the 16 patients having no
early improvement in psychotic symptoms after one week of
treatment, 11 did not respond (NPV ¼ 69%), 12 did not have
remission (NPV ¼ 75%, YMRS<13), while 13 failed to achieve
remission with a more stringent criteria (NPV ¼ 81%) at endpoint.
Sensitivity, speciﬁcity, and positive and negative predictive values
are summarized in the Table 2.
4. Discussion
Lithium monotherapy showed similar efﬁcacy in both mania
with and without psychosis in patients without rapid cycling or
mixed states. To the best of our knowledge, this is the ﬁrst study
showing that early improvement of psychotic symptoms predicts
later outcome with lithium monotherapy. Our results are in line
with other studies showing the efﬁcacy of lithium or divalproex
monotherapy (Swann et al., 2004), and lithium plus carbamazepine
(Small et al., 1995) for treating psychotic symptoms in mania.
Speciﬁcally, the response rates found in our study for both
psychosis (63%) and non-psychosis mania (64%) are slightly higher
than those observed in previous studies with lithiummonotherapy.
Improvement of psychotic symptoms in bipolar maniawith lithium
monotherapy was studied by Swann et al. (2002), who found
lithium treatment signiﬁcantly better than placebo for improving
mania in a psychotic subtype (derived from a previous cluster
analysis). In addition, lithium was compared to ﬁrst and second-
generation neuroleptics in mania with psychosis. Prien et al.
Fig. 1. Course of overall manic symptoms (total YMRS) with lithium treatment in
psychosis and non-psychosis mania.
Fig. 2. Relationship between change in YMRS item-8 (content) and YMRS total scores
from baseline to endpoint in psychotic Mania. YMRS e Young Mania Rating Scale.
Table 2
Analyses of early improvement in psychotic symptoms (delusions and hallucina-
tions within the ﬁrst week) in the psychosis group as a predictor of endpoint
outcome.
Sensitivity Speciﬁcity Positive
predictive
value
Negative
predictive
value
Response 75 92 94 69
Remission (YMRS  12) 75 75 75 75
Remission (YMRS  7) 73 62 50 81
Values displayed as percentages. YMRS e Young Mania Rating Scale. Response is
deﬁned as 50% improvement in YMRS total score from baseline to endpoint.
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(1972) found chlorpromazine superior to lithium in suspiciousness
measured by Brief Psychiatric Rating Scale (BPRS) and Keck et al.
(2009) found aripiprazole, but not lithium, more effective than
placebo in psychotic symptoms by Positive and Negative Syndrome
Scale (PANSS) scale. Bowden et al. (2005) found lithium and que-
tiapine similarly effective and superior to placebo in the treatment
of psychosis by PANSS positive subscale. In summary, the different
results foundmay be explained by the use of differentmethodology
and scales to compare lithium and antipsychotics for treating
mania with psychosis.
In the present study, lithium monotherapy produced early
improvement of psychotic symptoms in half of the patients after
1-week treatment. Early improvement of psychotic symptoms
(delusions and hallucinations) in the ﬁrst week of treatment
yielded high speciﬁcity and positive predictive value for later
clinical response at endpoint (week 4). Likewise, Ketter et al.
(2010) found that early improvement (i.e., improvement after 4
days) on ziprasidone predicted remission at 21 days according to
the Schedule for Affective Disorders and Schizophrenia-Change
(SADS-C). Another study looked at early improvement of manic
symptoms but did not evaluate improvement of psychosis. Kemp
et al. (2011a) found that patients without improvement in over-
all manic symptoms at week 1 (<25% decrease in YMRS total
score) with risperidone and olanzapine were less likely to reach
response and remission at week 3.
Furthermore, our results are in agreement with other studies in
different psychiatric conditions. Early improvement was found to
predict later outcome in studies with atypical antipsychotics in
schizophrenia (Kinon et al., 2008), antidepressants in unipolar
depression (Szegedi et al., 2009), and mood stabilizers and atypical
antipsychotics in bipolar depression (Kemp et al., 2011b).
Limitations include the exclusion of subjects with mixed
episodes and rapid cycling, gender differences between psychosis
and non-psychosis groups, and the lack of a speciﬁc rating scale for
quantifying psychotic symptoms (e.g., BPRS, PANSS).
In conclusion, lithium monotherapy showed similar efﬁcacy in
both mania with and without psychosis.
To our knowledge, this is the ﬁrst report to describe early
improvement of psychotic symptoms having a high positive
predictive value and signiﬁcant speciﬁcity for later response with
lithium therapy. The present ﬁndings reinforce the role of lithium
in the treatment of classic mania with psychotic features as well
as the importance of assessing improvement of psychosis in the
ﬁrst week of treatment as a predictor of subsequent outcome.
Further studies are necessary to conﬁrm these preliminary
ﬁndings.
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